Mode
Text Size
Log in / Sign up
N/A N=205 Randomized Treatment

Depression Attention for Women Now (The DAWN Study)

Depressive Disorder

Enrolled (actual)
205
Serious AEs
1.0%
Results posted
Aug 2014
Primary outcome: Primary: Depression Treatment Outcome — 0.96; 1.33 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Depression Care Management (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
University of Washington
Primary completion
May 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Depression Treatment Outcome
0.96; 1.33
PRIMARY
Functional Outcome
3.69; 4.03
SECONDARY
Quality of Depression Care Indicators
67; 28
SECONDARY
Potential Facilitators and Barriers to Sustainability

Summary

Major depressive disorder (MDD) is a common disabling illness that disproportionately affects women, with prevalence rates two times those of men. In addition to suffering, MDD has been shown to have a marked effect on social and vocational functioning, with increased disability, lost productivity, and excess mortality. Women with MDD have an increased prevalence of comorbid anxiety disorders and medical conditions. Our model of care utilizes a social worker as a depression care manager (DCM) to support both patients and physicians in optimizing care in the OB-GYN clinical setting. This intervention will be compared to usual care for depression.

Eligibility Criteria

Inclusion Criteria

  • PHQ-9 score ≥10 for Major Depressive Disorder (with 1 cardinal symptom) and/or ≥10 for Dysthymia (with 1 cardinal symptom)
  • MINI confirmation of PHQ-9 diagnoses
  • Access to a telephone
  • English-speaking

Exclusion Criteria

  • High suicide risk (PHQ-9 response)
  • ≥2 prior suicide attempts
  • Lifetime history of schizophrenia or bipolar disorder (MINI response)
  • Substance abuse/dependence within the previous 3 months (CAGE-AID)
  • Current severe intimate partner violence
  • Currently seeing a psychiatrist
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01096316). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search